Dr. med. univ. Moritz Ferch
Department of Medicine III (Clinical Division of Endocrinology and Metabolism)
Position: PHD Student
ORCID: 0000-0001-7786-8156
Keywords
Dyslipidemias; Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Rare Diseases
Research interests
My thesis focuses on strategies for improving cardiometabolic risk stratification, diagnostic yield, and therapeutic care for patients with dyslipidemia. Further research interests include inborn errors of metabolism as well as rare diseases.
Techniques, methods & infrastructure
Clinical Studies
Selected publications
- Ferch, M. et al. (2025) ‘Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome’, The Journal of Clinical Endocrinology & Metabolism, 110(12), pp. 3364–3369. Available at: https://doi.org/10.1210/clinem/dgaf258.
- Ferch, M. et al. (2024) ‘Performance of LDL-C only compared to the Dutch Lipid Clinic Network Score for screening of familial hypercholesterolaemia: the Austrian experience and literature review’, European Journal of Preventive Cardiology, 32(3), pp. 249–258. Available at: https://doi.org/10.1093/eurjpc/zwae331.
- Ferch, M. et al. (2024) ‘PCSK9 inhibitors in real life—Cardiometabolic risk management in dyslipidemic patients in Vienna’, Wiener klinische Wochenschrift, 137(9–10), pp. 307–313. Available at: https://doi.org/10.1007/s00508-024-02402-9.
- Fellinger, P. et al. (2022) ‘HbA1c and Glucose Management Indicator Discordance Associated with Obesity and Type 2 Diabetes in Intermittent Scanning Glucose Monitoring System’, Biosensors, 12(5), p. 288. Available at: https://doi.org/10.3390/bios12050288.